Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
The most effective method to Amplify Profits from Gold Speculation: Systems and Tips - 2Aluminum salts emerge as likely target as health officials scrutinize childhood vaccines
- 3Eleven Creations And Developments That Steered History
- 4Germany and trade unions kick off tough public-sector wage talks
- 5Holiday travel: Best days to hit the road as 110 million Americans expected to drive over Christmas and New Year's
- A definitive Cruiser Standoff: Decision in favor of Your #1 Ride
- Oldest evidence of human fire-making discovered at site in England
- James Webb Space Telescope watches 'Jekyll and Hyde' galaxy shapeshift into a cosmic monster
- Holiday destinations for Creature Sweethearts
- Savvy Watches: Which One Is Appropriate for You?
- Language Learning Stages: Which One Gets Your Vote?
- Figure out How to Track the Establishment of New 5G Pinnacles
- 6 Solid Moving Administrations for a Calm Movement
- Like many holiday traditions, lighting candles and fireplaces is best done in moderation
